龙血竭联合雷珠单抗治疗脉络膜新生血管的疗效观察  

The Effect of Dracaena Cochinchinensis and Ranibizumab in the Treatment of Choroidal Neovascularization

作　　者：韩崧[1] 

机构地区：[1]首都医科大学附属北京同仁医院眼科中心,北京100730

出　　处：《中医药学报》2017年第3期59-62,共4页Acta Chinese Medicine and Pharmacology

摘　　要：目的:观察单味中药龙血竭粉联合雷珠单抗治疗脉络膜新生血管的疗效。方法:选择我院门诊及住院2013年1月—2015年6月收治的70例确诊为脉络膜新生血管(CNV)患者作为研究对象,按随机数字表分为观察组35例(35只眼)和对照组35例(35只眼),对照组患者单纯行玻璃体腔注射雷珠单抗0.5 mg,1个月1次,连续注射3次,观察组在对照组的基础上再口服龙血竭粉,1.5 g/次,1天3次,连续服用3个月,治疗前后检测最佳矫正视力,进行眼底彩色照相测量眼底出血面积,进行眼底荧光造影测量黄斑区荧光渗漏面积,进行光学相干断层扫描测量外层高反光带厚度(OHRBT厚度),评价视力疗效、眼底出血疗效、CNV渗漏疗效及CNV厚度疗效。结果:观察组和对照组治疗后最佳矫正视力均较治疗前明显升高,差异具有统计学意义(均P<0.05),观察组治疗后最佳矫正视力明显高于对照组,差异具有统计学意义(均P<0.05)。观察组和对照组治疗后眼底出血面积、黄斑区荧光渗漏面积、OHRBT厚度均较治疗前明显降低,差异具有统计学意义(均P<0.05),观察组治疗后眼底出血面积、黄斑区荧光渗漏面积、OHRBT厚度均明显低于对照组,差异具有统计学意义(均P<0.05)。观察组视力疗效、眼底出血疗效、CNV渗漏疗效及CNV厚度疗效的总有效率均明显高于对照组,差异具有统计学意义(均P<0.05)。结论:龙血竭联合雷珠单抗治疗脉络膜新生血管的有效方法,能有效抑制脉络膜新生血管膜生长,改善患者的视功能、减轻荧光素渗漏、促进出血吸收,值得临床推广使用。Objective： To observe the effect of Dracaena cochinchinensis and Ranibizumab in the treatment of choroidal neovascularization （CNV）. Methods： 70 inpatients and outpatients with CNV from Jan. 2013 to Jun. 2015 were random- ly divided into the observation group（35eases -35eyes） and the control group （35cases -35eyes）. The control group was given three consecutive intravitreal Ranibizurnab （0.5 mg） , once a month; The observation group was given Dra- caena cochinchinensis powder （ 1.5 g, t. i. d. ） for three months on the basis of the control group＇ s treatment. The best corrected visual acuity （BCVA） was tested, the areas of fundus hemorrhagic and macular leakage were calculated re- spectively by color fundus photography and fluoreseein angiography, and the out - layer high reflective band thickness （OHRBT） was measured by optical coherence tomography（OCT） before and after treatment. Base on this, the efficacy of vision, retinal hemorrhage, CNV leakage and CNV thickness were evaluated. Results： The BCVA of the observation group and the control group were higher after treatment than those before treatment, and the difference was statistically significant （P 〈 0.05 ） ; Also, the BCVA of the observation group after treatment was better than that of the control group, the difference was statistically significant （ P 〈 0.05 ）. The areas of the fundus hemorrhagic and macular leak- age, and OHRBT of the observation group and the control group after treatment were smaller than those before treatment, and the differences were statistically significant （P 〈 0.05 ） ; The observation group was better improved than the control group, the difference was significant （ P 〈 0.05 ）. The total efficacy of vision, retinal hemorrhage, CNV leakage and CNV thickness of the observation group were higher than those of the control group, and the difference was statistically significant （ P 〈 0.05 ）. Conclusion ： Dracaena cochinchinensis and Ranibizumab is an effective w

关 键 词：脉络膜新生血管 龙血竭 雷珠单抗 临床研究 

分 类 号：R773.4[医药卫生—眼科]